Latest filing published 20 Dec 2024 for Prelude Therapeutics Inc, €22k. Read the official filing
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Bryant David Lim discloses dealings in 2 companies, chiefly Prelude Therapeutics Inc and Idera Pharmaceuticals, Inc. Over a trading history stretching from 6 January 2023 to 19 December 2024, the count stands at 3 filings.
Purchases make up the whole of the open-market record (2 purchases, €34k). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 1 share grant. 2024 to date brings 1 purchase and no sales.
On 20 December 2024 came the latest disclosure, an open-market purchase for €22k in Prelude Therapeutics Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations